Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Genetic factors in colorectal cancer, and Melanoma and MAPK Pathways.
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i> -Mutated Colorectal Cancer
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer
Author Correction: Progressive plasticity during colorectal cancer metastasis
FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers.
Automated real-world data integration improves cancer outcome prediction
Progressive plasticity during colorectal cancer metastasis
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer
Evidence for Unified Assessment Criteria of HER2 Immunohistochemistry in Colorectal Carcinoma
Analysis of Shared Variants between Cancer Biospecimens
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer
Alveolar Differentiation Drives Resistance to <i>KRAS</i> Inhibition in Lung Adenocarcinoma
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers
Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRAS<sup>G12C</sup> mutation.
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
Sotorasib in <i>KRAS</i> p.G12C–Mutated Advanced Pancreatic Cancer
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer